Takeda Pharmaceutical (TAK) Income from Non-Controlling Interests (2017 - 2026)

Takeda Pharmaceutical's Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at $395346.1 for Q1 2026.

• On a quarterly basis, Income from Non-Controlling Interests rose 160.32% year-over-year to $395346.1 in Q1 2026; TTM through Mar 2026 was -$2.3 million, a 1.01% increase from a year earlier, with the FY2026 full-year figure at $1.8 million, up 24.26% from the prior year.
• Income from Non-Controlling Interests advanced to $395346.1 in Q1 2026 per TAK's latest filing, from -$649790.1 in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $395346.1 in Q1 2026 and bottomed at -$1.4 million in Q3 2025.
• The 5-year median for Income from Non-Controlling Interests is -$649790.1 (2025), against an average of -$395010.0.
• Across the five-year window, Income from Non-Controlling Interests slumped 856.34% in 2023 and jumped 308.17% in 2024, its largest moves.
• Year by year, Income from Non-Controlling Interests stood at $155723.0 in 2022, then plunged by 544.66% to -$692442.5 in 2023, then gained by 5.01% to -$657777.5 in 2024, then gained by 1.21% to -$649790.1 in 2025, then jumped by 160.84% to $395346.1 in 2026.
• Per Business Quant, the three latest TAK Income from Non-Controlling Interests figures stand at $395346.1 (Q1 2026), -$649790.1 (Q4 2025), and -$1.4 million (Q3 2025).